Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches

Antiplatelet agents, with aspirin and P2Y(12) receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jourdi, Georges, Godier, Anne, Lordkipanidzé, Marie, Marquis-Gravel, Guillaume, Gaussem, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832164/
https://www.ncbi.nlm.nih.gov/pubmed/35155631
http://dx.doi.org/10.3389/fcvm.2022.805525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832164/
https://www.ncbi.nlm.nih.gov/pubmed/35155631
http://dx.doi.org/10.3389/fcvm.2022.805525

Ejemplares similares